Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autoimmune Basis for POTS
NCT02725060Enrolling by invitation
- Sponsor
- Vanderbilt University Medical Center
- Start
- Feb 2016
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Open-label trial, sponsored by Vanderbilt University Medical Center. Primary endpoints: Autoantibody levels at 10 months, Blood pressure after phenylephrine boluses at 2 months and 1 more. Started Feb 2016; status: enrolling by invitation.
Beyond the preview
Go deeper on NCT02725060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725060.